Revefenacin helps patients with moderate to severe COPD
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability, investigation is essential for better management in both men and women.
A randomized trial by Gary Ferguson and team revealed that nebulized revefenacin produced significant improvements in COPD Assessment Test (CAT) scores in women and men with moderate to very severe COPD, they also revealed significant improvements in St George's Respiratory Questionnaire (SGRQ) scores in women alone when compared with placebo. Maintenance treatment with revefenacin can improve health status of patients with moderate to very severe COPD; however, the effect may be more pronounced in women than men.
For more details, check out the full story on the link below:
Nebulized Revefenacin Improves Health Status Of Patients With Moderate To Very Severe COPD: Study
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.